Möchten Sie immer auf dem neuesten Stand bleiben?

Brussels, 19 April 2005 - Following Pfizer's first quarter 2005 earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine...

Tokyo (Japan) - April 18, 2005 - UCB Japan Co., Ltd. (UCB Japan) and GlaxoSmithKline K.K. (GSK Japan) announced that GSK Japan will be the new codistributor for Zyrtec® tablet 5mg and Zyrtec® tablet...

Brussels, April 18, 2005 - UCB, a leading global biopharmaceutical company, today confirmed that its novel oxybutynin transdermal patch for overactive bladder (OAB) is to begin its phased European...

Brussels, BELGIUM, 31 March 2005) - UCB today announced the first evidence from a major study showing that Keppra® (levetiracetam) is effective for adjunctive treatment of myoclonic seizures in...

Financial Highlights UCB Group confirms net income after tax increased by 7% to € 363 million (19% at constant exchange rates) under Belgian GAAP. Dividend increases by 5%. IFRS conversion...

Brussels - March 1st, 2005 - UCB confirms today the closing of sale of its Surface Specialties business to Cytec Industries Inc. a global technology leader in specialty chemicals and specialty...

Brussels, 17 February 2005: UCB Pharma Inc has been granted a priority review for the supplemental new drug application (sNDA) seeking approval of its leading anti-epilepsy drug (AED) Keppra®*...

Continued growth in a year of transformationNet Profit after tax increases by 6% (19% at constant exchange rates) UCB's 2004 net profit after tax of € 362 million was up 6% in real terms (19% at...

UCB Pharma to Develop through Phase II; Millennium Retains Development and Commercialization Options   Brussels, 25 January 2005 - UCB Pharma's Celltech Antibody Research Centre of Excellence...

Brussels, 19 January 2005 - Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine in the...